COVID-19 Vaccine – Epidemiology – Mature Markets
Clarivate Epidemiology's coverage of the COVID-19 vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of COVID-19 vaccine-eligible populations for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology's COVID-19 vaccine forecast will answer the following questions:
- How many medical doctors and nurses are there in the major mature markets? These front-line workers are among those recommended for booster / additional doses of the COVID-19 vaccine.
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the COVID-19 vaccination in the elderly population over the forecast period?
- How many people younger than age 65 are at high risk for complications from COVID-19?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. Clarivate Epidemiology provides at least ten years of forecast data for the following COVID-19 vaccine patient populations:
- Total number of medical doctors and nurses.
- Total number of people older than age 65.
- Total number of people younger than age 65 who have chronic conditions that put them at high risk for COVID-19 complications.
Note: coverage may vary by country and region.
Table of contents
- COVID-19 Vaccine - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of COVID-19 vaccine-eligible population)
- Healthcare workers
- COVID-19 vaccine-eligible older population
- COVID-19 high-risk population younger than age 65
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation table
Julie Davis, M.P.H., is an associate epidemiologist at Clarivate. Previously, she was a research assistant at Tufts Medical Center, where she studied accelerated osteoarthritis and other rheumatic diseases. She also has experience working with zoonotic disease transmission and excess mortality in Puerto Rico stemming from Hurricane Maria. She was part of the Health Emergencies team at the Pan American Health Organization, working on disaster preparedness and disease risk assessments. Ms. Davis received her M.P.H. in global health epidemiology and disease control from George Washington University and holds a bachelor’s degree in health sciences from James Madison University.